Literature DB >> 22223533

Heligmosomoides polygyrus abrogates antigen-specific gut injury in a murine model of inflammatory bowel disease.

John Leung1, Long Hang, Arthur Blum, Tommy Setiawan, Korynn Stoyanoff, Joel Weinstock.   

Abstract

BACKGROUND: Developing countries have a low incidence of inflammatory bowel disease (IBD), perhaps prevented by the high prevalence of helminth infections and other alterations in intestinal flora and fauna. Helminth infections prevent colitis in various murine models of IBD. IBD may be driven by an aberrant immune response to luminal antigen(s).
METHODS: We developed a murine model of IBD in which gut injury was induced by a specific antigen to better simulate the IBD disease process and to determine if helminth infections could abolish gut injury induced by an orally administered antigen. The model features pan-enterocolitis triggered by feeding ovalbumin (OVA).
RESULTS: The intestinal inflammation is antigen-specific and generates interleukin (IL)-17 and interferon-gamma (IFN-γ), but not IL-4. Full expression of the disease required T cells with defective capacity to make IL-10 and treatment with a noninjurious, low dose of a nonsteroidal antiinflammatory drug. Exposure to Heligmosomoides polygyrus abrogated this antigen-induced gut injury. H. polygyrus colonization induced Foxp3(+) T regulatory cells (Tregs) and mucosal production of IL-10 from non-T cells. Lamina propria mononuclear cells from H. polygyrus-infected mice released less IL-17 and IFN-γ constitutively and when stimulated with OVA or anti-CD3/CD28 monoclonal antibodies.
CONCLUSIONS: We developed a murine IBD model featuring antigen-specific enterocolitis and demonstrate for the first time that gut inflammation induced by an antigen could be abrogated by H. polygyrus infection. Protection was associated with suppressed IL-17 and IFN-γ production, induction of Foxp3(+) Tregs, and elevated secretion of non-T-cell-derived IL-10, all of which could be part of the protective processes.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22223533      PMCID: PMC4123417          DOI: 10.1002/ibd.22858

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  36 in total

1.  Exposure to schistosome eggs protects mice from TNBS-induced colitis.

Authors:  David E Elliott; Jie Li; Arthur Blum; Ahmed Metwali; Khurram Qadir; Joseph F Urban; Joel V Weinstock
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-11-13       Impact factor: 4.052

2.  Rapid development of colitis in NSAID-treated IL-10-deficient mice.

Authors:  Daniel J Berg; Juan Zhang; Joel V Weinstock; Hanan F Ismail; Keith A Earle; Hector Alila; Rifat Pamukcu; Steven Moore; Richard G Lynch
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

3.  CD4 T cells monospecific to ovalbumin produced by Escherichia coli can induce colitis upon transfer to BALB/c and SCID mice.

Authors:  M Yoshida; T Watanabe; T Usui; Y Matsunaga; Y Shirai; M Yamori; T Itoh; S Habu; T Chiba; T Kita; Y Wakatsuki
Journal:  Int Immunol       Date:  2001-12       Impact factor: 4.823

4.  Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1.

Authors:  R Zeidler; M Csanady; O Gires; S Lang; B Schmitt; B Wollenberg
Journal:  FASEB J       Date:  2000-04       Impact factor: 5.191

Review 5.  Prostaglandins and leukotrienes: advances in eicosanoid biology.

Authors:  C D Funk
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

Review 6.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance.

Authors:  S Sakaguchi; N Sakaguchi; J Shimizu; S Yamazaki; T Sakihama; M Itoh; Y Kuniyasu; T Nomura; M Toda; T Takahashi
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

Review 7.  The regulation of IL-10 production by immune cells.

Authors:  Margarida Saraiva; Anne O'Garra
Journal:  Nat Rev Immunol       Date:  2010-02-15       Impact factor: 53.106

8.  Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis.

Authors:  Anne Camille La Flamme; Kate Ruddenklau; B Thomas Bäckström
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis).

Authors:  Judith Satoguina; Martin Mempel; John Larbi; Marlis Badusche; Cornelius Löliger; Ohene Adjei; Gabriel Gachelin; Bernhard Fleischer; Achim Hoerauf
Journal:  Microbes Infect       Date:  2002-11       Impact factor: 2.700

10.  T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis.

Authors:  Nuzhat Iqbal; James R Oliver; Frederic H Wagner; Audrey S Lazenby; Charles O Elson; Casey T Weaver
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

View more
  16 in total

Review 1.  Therapeutic potential of helminths in autoimmune diseases: helminth-derived immune-regulators and immune balance.

Authors:  Meng Wang; Linxiang Wu; Rennan Weng; Weihong Zheng; Zhongdao Wu; Zhiyue Lv
Journal:  Parasitol Res       Date:  2017-06-29       Impact factor: 2.289

2.  Hookworm-Derived Metabolites Suppress Pathology in a Mouse Model of Colitis and Inhibit Secretion of Key Inflammatory Cytokines in Primary Human Leukocytes.

Authors:  Phurpa Wangchuk; Catherine Shepherd; Constantin Constantinoiu; Rachael Y M Ryan; Konstantinos A Kouremenos; Luke Becker; Linda Jones; Geraldine Buitrago; Paul Giacomin; David Wilson; Norelle Daly; Malcolm J McConville; John J Miles; Alex Loukas
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

3.  Mitigation of Toxoplasma gondii-induced ileitis by Trichinellaspiralis infection pinpointing immunomodulation.

Authors:  Enas F Abdel Hamed; Nahed E Mostafa; Mohsen M Hassan; Mohamed N Ibrahim; Said Mahmoud Elraey; Mona Radwan; Al-Sayed R Al-Attar; Eman M Fawzy
Journal:  J Parasit Dis       Date:  2022-03-03

Review 4.  Helminth infections and host immune regulation.

Authors:  Henry J McSorley; Rick M Maizels
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 5.  Linking the Microbiota, Chronic Disease, and the Immune System.

Authors:  Timothy W Hand; Ivan Vujkovic-Cvijin; Vanessa K Ridaura; Yasmine Belkaid
Journal:  Trends Endocrinol Metab       Date:  2016-09-10       Impact factor: 12.015

Review 6.  Translatability of helminth therapy in inflammatory bowel diseases.

Authors:  Joel V Weinstock; David E Elliott
Journal:  Int J Parasitol       Date:  2012-11-21       Impact factor: 3.981

7.  Extraintestinal Helminth Infection Limits Pathology and Proinflammatory Cytokine Expression during DSS-Induced Ulcerative Colitis: A Role for Alternatively Activated Macrophages and Prostaglandins.

Authors:  Yadira Ledesma-Soto; Blanca E Callejas; César A Terrazas; Jose L Reyes; Arlett Espinoza-Jiménez; Marisol I González; Sonia León-Cabrera; Rosario Morales; Jonadab E Olguín; Rafael Saavedra; Steve Oghumu; Abhay R Satoskar; Luis I Terrazas
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

8.  Excretory/secretory products from Trichinella spiralis adult worms ameliorate DSS-induced colitis in mice.

Authors:  Xiaodi Yang; Yaping Yang; Yunyun Wang; Bin Zhan; Yuan Gu; Yuli Cheng; Xinping Zhu
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

9.  Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice.

Authors:  Shushu Wang; Yuanyuan Xie; Xiaodi Yang; Xuesong Wang; Ke Yan; Zhengrong Zhong; Xiaowei Wang; Yuanhong Xu; Yi Zhang; Fang Liu; Jilong Shen
Journal:  Parasit Vectors       Date:  2016-01-04       Impact factor: 3.876

10.  Regulation of type 2 diabetes by helminth-induced Th2 immune response.

Authors:  Motoko Morimoto; Noritsugu Azuma; Hikaru Kadowaki; Tatsuya Abe; Yoshiko Suto
Journal:  J Vet Med Sci       Date:  2016-09-22       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.